Skip to main content
SpringerLink
Log in

Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Herpes simplex virus (HSV) mutants kill dividing tumor cells but spare non-proliferating, healthy brain tissue and may be useful in developing new treatment strategies for malignant brain tumors. Two HSV mutants, a thymidine kinase deficient virus (TK-) and a ribonucleotide reductase mutant (RR-), killed 7/7 human tumor cell lines in tissue culture. The TK-HSV killed Rat RG2 glioma and W256 carcinoma lines but not the rat C6 glioma in culture. TK-HSV replication (12 pfu/cell) was similar to wild-type HSV (10 pfu/cell) in rapidly dividing W256 cells in tissue culture, but was minimal (<1 pfu/cell) in serum-starved cells, suggesting that the proliferative activity of tumor cells at the site and time of TK-HSV injection may influence efficacyin vivo. Subcutaneous W256 tumors in male Sprague-Dawley rats were injected with TK-HSV or virus free inoculum. A significant effect of TK-HSV therapy on W256 tumor growth was demonstrated compared to controls (p=0.002). Complete regression was observed in 4/9 experimental tumors, with no recurrence over 6 months. Tumor growth in the remaining 5/9 animals was attenuated during the first 3 to 5 days after treatment, but not beyond 5 days compared to 9 matched control animals; no tumor regression was observed in any of the control animals. These results suggest that HSV mutants are potentially useful as novel therapeutic agents in the treatment of tumors in immunocompetent subjects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Committee on Health Care Issues, American Neurological Association: Chemotherapy for malignant gliomas. Ann Neurol 25: 88–89

  2. Stewart DJ: The role of chemotherapy in the treatment of gliomas in adults. Canc Treat Rev 16: 129–160, 1989

    Google Scholar 

  3. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WHet al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. New Eng J of Med 303: 1323–1329, 1978

    Google Scholar 

  4. Cassel WA, Murray DR, Phillips HS: A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52: 856–860, 1983

    Google Scholar 

  5. Taylor MW, Cordell B, Southrada M, Prather S: Viruses as an aid to cancer therapy: regression of solid and ascites tumors in rodents after treatment with bovine enterovirus. Proc Natl Acad Sci USA 68: 836–840, 1971

    Google Scholar 

  6. Sharpless NE, O'Brien WA, Verdin E, Kufta CV, Chen ISY, Dubois-Dalcq M: Human immunodeficiency virus type 1 tropsim for brain microglial cells is determined by a region of the env glycoprotein that also controls macrophage tropism. J Virol 66: 2588–2593, 1992

    Google Scholar 

  7. Dulbecco R, Ginsberg HS: Virology. Harper and Row, Philadelphia, 1980

    Google Scholar 

  8. Roizman B, Batterson W: The replication of herpes viruses. In: Fields B (ed.) General Virology, pp 497–526. Raven Press, New York, 1984

    Google Scholar 

  9. Wagner EK: In: Roizman B (ed.) The Herpes viruses. New York, Plenum Press: 288–321, 1985

    Google Scholar 

  10. Dubbs DR, Kit S: Mutant strains of herpes simplex deficient in thymidine kinase-induced activity. Virology 22: 493–502, 1964

    Google Scholar 

  11. Goldstein DJ, Weller SK: Herpes simplex virus type-1 induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62: 196–205, 1988

    Google Scholar 

  12. McGeoch DJ, Weller SK, Schaffer PA: Genetic Maps. CSHL Press: 1.115–1.120,1990

  13. Jamieson AT, Gentry GA, Subak-Sharpe JH: Induction of both thymidine and deoxytidine kinase activity by herpes simplex virus. J Gen Virol 24: 465–480, 1974

    Google Scholar 

  14. Engstrom Y, Rozell B, Hansson HA, Stemme S, Thelander L: Localization of ribonucleotide reductase in mammalian cells. EMBO J 3: 863–867, 1984

    Google Scholar 

  15. Field HJ, Darby G: Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovirin vitro andin vivo. Animicrob Agent Chemother 17: 209–216, 1980

    Google Scholar 

  16. Thelander C, Reichard P: Reduction of ribonucleotides. Ann Rev Biochem 48: 133–158, 1979

    Google Scholar 

  17. Cowan M, Davies J, Brookes K, Billstrom M, McLeish P, Buchan A, Skinner GR: Inhibition of rate of tumor growth in rodent species by inoculation of herpes viruses and encephalomyocarditis virus. J Med Virol 30: 211–215, 1990

    Google Scholar 

  18. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854–855, 1991

    Google Scholar 

  19. Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM: Thymidine kinase negative herpesvirus mutants establish latency in mouse trigeminal ganglia, but do not reactivate. Proc Nat Acad Sci 86: 4736–4740, 1989

    Google Scholar 

  20. DeLuca NA, Courtney MA, Schaffer PA: Temperature sensitive mutants in HSV-1 ICP4 permissive for early gene expression. J Virol 52: 767–776, 1984

    Google Scholar 

  21. Kaplitt MG, Pfaus JG, Kleopoulos SP, Hanlon BA, Rabkin SD, Pfaff DW: Expression of a functional foreign gene in adult mammalian brain followingin vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol Cell Neurosci 2: 320–330, 1991

    Google Scholar 

  22. Blasberg RG, Groothuis D, Molnar P: Application of quantitative autoradiographic measurements in experimental brain tumor models. Semin Neurol 1: 203–223, 1981

    Google Scholar 

  23. Blasberg RG, Shapiro WR, Molnar R, Patlak CS, Fenstermacher JD: Local blood flow in Walker 256 metastatic brain tumors. J Neuro-Oncol 2: 195–204, 1984

    Google Scholar 

  24. Hoshino T, Nagashima T, Murovic J, Wilson CB, Edwards MSB, Gutin PH, Davis RL, DeArmond SJ:in situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling. J Neurosurg 64: 453–459, 1986

    Google Scholar 

  25. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK, Coen DM: A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivalable latent infection of mice and for replication in mouse cells. Virology 173: 276–283, 1989

    Google Scholar 

  26. Turk SR, Kik NA, Birch GM, Chiego DJ, Shipman C: Herpes simplex virus type 1 ribonucleotide reductase null mutants induce lesions in guinea pigs. Virology 173: 733–735, 1989

    Google Scholar 

  27. Bagshaw M, Doggett R, Smith K, Kaplan H, Nelsen T: Intraarterial 5-bromodeoxyuridine and X-ray therapy. Radiology 99: 886–894, 1967

    Google Scholar 

  28. Hoshino T, Prados M, Wilson C, Cho K, Lee K, Davis R: Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg 71: 335–341, 1989

    Google Scholar 

  29. Hoshino T, Rodriguez L, Cho K, Lee KS, Wilson CB, Edwards MS, Levin VA, Davis RL: Prognostic implications of the proliferative potential of low-grade astrocytomas. J Neurosurg 69: 839–842, 1988

    Google Scholar 

  30. Bresnik E, Thompson VB: Properties of deoxythymidine kinase partially purified from animal tumors. J Biol Chem 240: 3967, 1965

    Google Scholar 

  31. Kit S, Dubbs D: Properties of deoxythymidine kinase partially purified from non-infected and virus-infected mouse fibroblast cells. Virology 26: 16–27, 1965

    Google Scholar 

  32. Voytek P, Chang PK, Prusoff W: Purification of deoxythymidine kinase by preparative disk gel electrophoresis and the effects of various halogenated nucleoside triphosphates on its enzymatic activity. J Biol Chem 246: 1432–1438, 1971

    Google Scholar 

  33. Roszman T, Elliott L, Brooks W: Modulation of t-cell function by gliomas. Immunology Today 12(10): 370–374, 1991

    Google Scholar 

  34. Kuppner MC, Hamou MF, Tribolet N: Activation and adhesion molecule expression on lymphoid infiltrates in human glioblastomas. J of Neuroimmunology 29: 229–238, 1990

    Google Scholar 

  35. Sawamura Y, Abe H, Aida T, Hosokawa M, Kobayashi H: Isolation andin vitro growth of glioma-infiltrating lymphocytes, and an analysis of their surface phenotypes. J Neurosurg 69: 745–750, 1988

    Google Scholar 

  36. Corey L, Spear PG: Infections with herpes simplex viruses. N Eng J of Med 314: 686–691, 1986

    Google Scholar 

  37. Roizman B, Jenkins FJ: Genetic engineering of novel genomes of large DNA viruses. Science 229: 1208–1214, 1985

    Google Scholar 

  38. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM:In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550–1552, 1992

    Google Scholar 

  39. Ezzedine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, Breakefield XO: Selective killing of glioma cells in culture andin vivo by retrovirus transfer for the herpes simplex virus thymidine kinase gene. New Biol 3: 608–614, 1991

    Google Scholar 

  40. Challberg MD, Kelly TJ: Animal virus DNA replication. Annu Rev biochem 58: 671–717, 1989

    Google Scholar 

  41. Gray DA: Insertional mutagenesis: neoplasia arising from retroviral integration. Cancer Invest 9: 295–304, 1991

    Google Scholar 

  42. Gilboa E: Retrovirus vectors and their uses in molecular biology. BioEssays 5: 252–257, 1987

    Google Scholar 

  43. Miller DG, Adam MA, Miller AD: Gene transfer by retro-virus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10: 4239–4242, 1990

    Google Scholar 

  44. Hoshino T, Barker M, Wilson CB, Boldrey EB, Fewer D: Cell kinetics of human gliomas. J Neurosurg 37: 15–26, 1972

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neurobiology and Behavior, Rockefeller University, 10021, New York, NY

    Michael G. Kaplitt & Donald W. Pfaff

  2. Department of Neurology, Memorial Sloan Kettering Cancer Center, 10021, New York, NY

    Juri G. Tjuvajev, Jeffrey Berk, Jerome B. Posner & Ronald G. Blasberg

  3. Program in Molecular Biology, Memorial Sloan Kettering Cancer Center, 10021, New York, NY

    Samuel D. Rabkin

  4. Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, 63110, St. Louis, MO

    David A. Leib

  5. Division of Applied and Services Research, National Institute of Mental Health, 20892, Bethesda, MD

    Karen D. Pettigrew

Authors
  1. Michael G. Kaplitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juri G. Tjuvajev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David A. Leib
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey Berk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karen D. Pettigrew
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jerome B. Posner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Donald W. Pfaff
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Samuel D. Rabkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ronald G. Blasberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaplitt, M.G., Tjuvajev, J.G., Leib, D.A. et al. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neuro-Oncol 19, 137–147 (1994). https://doi.org/10.1007/BF01306455

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01306455

Key words

Search

Navigation